Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D.

Haematologica. 2006 Oct;91(10):1343-51.

2.

Developmental changes in patterns of expression of tenascin-C variants in the human cornea.

Maseruka H, Ridgway A, Tullo A, Bonshek R.

Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4101-7.

PMID:
11095602
3.

Human herpesviruses in the cornea.

Kaye SB, Baker K, Bonshek R, Maseruka H, Grinfeld E, Tullo A, Easty DL, Hart CA.

Br J Ophthalmol. 2000 Jun;84(6):563-71.

4.

Tenascin-cytotactin (TN-C) variants in pseudophakic/aphakic bullous keratopathy corneas.

Maseruka H, Ataullah SM, Zardi L, Tullo AB, Ridgway AE, Bonshek RE.

Eye (Lond). 1998;12 ( Pt 4):729-34.

PMID:
9850274
5.

Tenascin-C expression in normal, inflamed, and scarred human corneas.

Maseruka H, Bonshek RE, Tullo AB.

Br J Ophthalmol. 1997 Aug;81(8):677-82.

6.

Immunohistochemical appearance of corticosteroid contact hypersensitivity reactions.

Wilkinson SM, Andrew SM, Maseruka H, Beck MH.

Contact Dermatitis. 1994 Nov;31(5):304-7.

PMID:
7532558

Supplemental Content

Loading ...
Support Center